What is PT-141?

PT-141, also known as bremelanotide, is a synthetic melanocortin receptor agonist. It is commonly discussed in research settings for its activity on melanocortin receptors, particularly MC3R and MC4R, which are involved in arousal, reward signalling and sexual desire pathways.

PT-141 is related to Melanotan II, but it is usually discussed for a different purpose. Rather than being primarily associated with pigmentation, PT-141 is more commonly discussed for sexual desire, arousal signalling and central nervous system pathways.

PT-141 Reconstitution Example

The example below is based on a common 10mg PT-141 vial mixed with 3.0mL bacteriostatic water.

Standard / Gradual Research Protocol Example

This example uses a 10mg vial reconstituted with 3.0mL bacteriostatic water, giving an approximate concentration of 3.33mg/mL.

Route and Frequency Notes

PT-141 is most commonly discussed as a subcutaneous compound in research and clinical contexts. Subcutaneous administration is usually described in areas such as the abdomen or thigh, with rotation of injection sites to reduce irritation.

Clinical bremelanotide references also describe on-demand subcutaneous use. Some research discussions refer to once-daily approaches, while other references focus on occasional or event-based use. Because context matters, this page should be treated as a reconstitution and measurement guide rather than a personal protocol.

Reconstitution Steps

1. Confirm the vial size before calculating concentration.
2. Draw 3.0mL bacteriostatic water using sterile technique.
3. Inject the bacteriostatic water slowly down the inside wall of the vial.
4. Avoid blasting the powder directly and avoid creating foam.
5. Gently swirl or roll the vial until the powder is fully dissolved.
6. Do not shake aggressively.
7. Label the vial with the reconstitution date.
8. Store the reconstituted vial in the refrigerator at 2-8°C, protected from light.

Supplies Needed

The following example is based on a gradual 8-16 week research schedule using 10mg PT-141 vials.

Protocol Overview

• Goal discussed in research: support sexual desire and arousal signalling through melanocortin receptor activation.
• Schedule example: daily subcutaneous use for 8-12 weeks, with some extended examples going to 16 weeks.
• Example amount range: 500-1500mcg daily using gradual titration.
• Example reconstitution: 3.0mL bacteriostatic water per 10mg vial.
• Storage: lyophilised vials stored frozen or cool as directed, reconstituted vials refrigerated.

How PT-141 Works

PT-141 is a synthetic analogue of alpha-melanocyte-stimulating hormone and acts as a non-selective melanocortin receptor agonist. It is most often discussed for activity at MC3R and MC4R.

In the central nervous system, MC4R activation is associated with dopamine signalling in reward and arousal-related brain regions. This is why PT-141 is often discussed differently from compounds that primarily act through blood flow pathways.

PT-141 may also have peripheral melanocortin effects, which helps explain why side effects such as flushing, nausea, blood pressure changes and pigmentation changes can occur in some settings.

Potential Benefits Discussed in Research

• Sexual desire and libido signalling
• Arousal pathways
• Central melanocortin receptor activation
• Dopamine-related reward and motivation pathways
• Possible appetite and body weight effects in some research contexts

Reported Side Effects

PT-141 can cause noticeable side effects, particularly when higher amounts are used or when tolerance has not been assessed gradually.

• Nausea
• Flushing
• Headache
• Injection site irritation
• Temporary blood pressure increases
• Skin darkening or pigmentation changes
• Appetite changes in some reports
• General discomfort or fatigue in some users

Storage Instructions

• Lyophilised powder: store frozen or cool, dry and protected from light as directed by the supplier.
• After reconstitution: refrigerate at 2-8°C.
• Avoid: heat, sunlight, repeated freeze-thaw cycles and leaving the vial at room temperature for extended periods.
• Practical note: allow cold vials to sit briefly before opening to reduce condensation exposure.

Injection Technique Notes

This section is general educational information only. It is not a personal injection instruction.

• Use a new sterile insulin syringe each time.
• Clean the vial stopper and skin with alcohol and allow to dry.
• Common subcutaneous sites discussed include abdomen and thigh.
• Rotate injection sites to reduce irritation.
• Insert into subcutaneous tissue at an appropriate angle based on needle length and body composition.
• Inject slowly and steadily.
• Dispose of used sharps safely in a sharps container.

Lifestyle Factors That May Matter

• Sleep: poor sleep can negatively affect libido, mood and hormonal signalling.
• Stress: chronic stress may reduce sexual desire and arousal.
• Alcohol: alcohol may blunt arousal pathways and worsen side effects such as nausea or headache.
• Exercise and diet: general health habits can influence libido and overall wellbeing.

Intranasal PT-141 Research Summary

PT-141 was previously studied using intranasal delivery before subcutaneous bremelanotide became the better-known clinical route. Intranasal research has been reported in both male erectile dysfunction and female sexual arousal disorder contexts.

• Route studied: intranasal delivery using metered-dose nasal spray devices.
• Male ED research: intranasal bremelanotide was studied in men with erectile dysfunction, with some trials reporting improved erectile response compared with placebo.
• Female arousal research: intranasal bremelanotide was studied in premenopausal women with female sexual arousal disorder, with reported increases in arousal and desire measures.
• Bioavailability issue: intranasal absorption was reported as lower and more variable than subcutaneous administration.
• Blood pressure concern: intranasal delivery was associated with more pronounced transient blood pressure changes in some research.
• Key limitation: nasal absorption depends heavily on device output, nasal technique and individual mucosal absorption.

Nasal Spray Device Output & Conversion Maths

Nasal spray devices vary in how much liquid they deliver per spray. The amount delivered depends on the device, priming, solution concentration and actual spray volume.

Example 1: mL-based pump

If a 10mg PT-141 vial is mixed with 3.0mL, the concentration is approximately 3,333mcg/mL. If a nasal pump delivers 0.10mL per actuation:

• 3,333mcg/mL × 0.10mL = approximately 333mcg per spray
• 1mL contains approximately 10 sprays
• 3.0mL contains approximately 30 sprays

Example 2: Unit-based pump estimate

If a device delivers approximately 13 U-100 style units per spray, this equals 0.13mL. Using the same 3,333mcg/mL concentration:

• 0.13mL × 3,333mcg/mL = approximately 433mcg per spray
• 1mL contains approximately 7.7 sprays
• 3.0mL contains approximately 23 sprays

Use the Peptide Calculator

If your vial size, water volume or target amount is different, use the Peptide Hub Australia calculator to work out concentration, mL and syringe units.

Where to Compare PT-141 Suppliers

Peptide Hub Australia does not sell PT-141. We compare Australian peptide vendors, package audits, pricing and supplier information to help users review the market more clearly.

Frequently Asked Questions

How much BAC water do you add to a 10mg PT-141 vial?

A common educational example is 3.0mL bacteriostatic water added to a 10mg vial, creating an approximate concentration of 3.33mg/mL.

How many units is 500mcg of PT-141?

If a 10mg vial is mixed with 3.0mL, 500mcg is approximately 15 units on a U-100 insulin syringe.

How many units is 1000mcg of PT-141?

Using the same 10mg in 3.0mL example, 1000mcg is approximately 30 units on a U-100 insulin syringe.

Can PT-141 cause nausea?

Yes. Nausea is one of the most commonly discussed side effects of PT-141 and appears to be dose-related in many reports.

Does PT-141 affect blood pressure?

Temporary blood pressure increases have been reported in clinical and research contexts. People with blood pressure or cardiovascular concerns should be especially cautious and seek professional advice.

Is this a personal dosing recommendation?

No. This page is an educational reconstitution and measurement guide only. It is not medical advice or a personal protocol.

Related Resources

• Peptide Calculator
• Compare Australian Peptide Vendors
• Compare Peptide Prices
• Package Audits